The Clinical Analysis On Mismatched Repair Protein And The Clinicopathological Features Of Endometrial Carcinoma

Research purpose:The purpose of this study is to analyze the relationship between mismatched repair proteins and the clinicopathological features of endometrial cancer retrospectively,in order to explore the clinicopathological features of endometrial cancer with MMR protein expression deficiency and also to provide theoretical basics for clinicians.Research methods:A total of 221 patients with endometrial cancer confirmed by surgery and postoperative pathology in our hospital from December 2018 to October 2019 were collected.We collected and sorted out the clinicopathological datum,according to the clinicopathological datum,We analyzed the clinicopathologic features of endometrial carcinoma with MMR protein expression deficiency.Research results:Among the 221 patients with endometrial cancer,50 patients had MMR protein expression deficiency,and the MMR expression deficiency rate was about 22.6%.The MLH1,MSH2,MSH6 and PMS2 protein expression deleters were 32,15,12 and 30 cases,with the MMR protein expression deficiency rates of 14.48%,6.79%,5.43%and 13.57%,respectively.The expression deficiency rate of MLH1 and PMS2 was12.22%.The expression deficiency rate of MSH6 and MSH2 was 4.07%.The expression deficiency rate of MSH6 and PMS2 was 0.45%.The expression deficiency rate of MLH1,MSH2 and PMS2 was 0.45%.We analyzed the clinicopathological features of endometrial cancer with MMR protein expression deficiency: 1.The MMR protein expression deficiency rate were 32.3% and 18.6% in the ≤50 years old group and the >50 years old group,respectively,with statistically significantdifferences(X2=4.932;P<0.05).2.The MMR protein expression deficiency rates were29.3% and 17.2% in the BMI < 25 group and the BMI ≥25 group,respectively,with statistically significant differences(X2=4.556;P < 0.05).3.The MMR protein expression deficiency rates were 20.5% and 23.2% in the diabetes group and the normal blood glucose group,respectively,with no statistically significant differences(X2=0.148;P>0.05).4.The MMR protein expression deficiency rates were25.0% and 21.8% in the hypertensive group and the non-hypertensive group,respectively,with no statistically significant differences(X2=0.242;P>0.05).5.The MMR protein expression deficiency rates were 16.7% and 23.0% in the personal history of tumor group and the no personal history of tumor group,respectively,with no statistically significant differences(X2=0.257;P > 0.05).6.The MMR protein expression deficiency rates were 45.5% and 21.4% in the Family history of tumor group and the no Family history of tumor group,respectively,with no statistically significant differences(X2=3.447;P > 0.05).7.The MMR protein expression deficiency rates were 24.5% and 0.0% in the endometrioid carcinoma group and the special pathological type group,respectively,with statistically significant differences(X2=5.385;P < 0.05).8.The MMR protein expression deficiency rate were 22.1%and 22.9% in the deep muscle infiltration group and the superficial muscle infiltration group,respectively,with no statistically significant differences(X2=0.02;P>0.05).9.MMR protein expression deficiency rates were 44.8% and 19.3% in the lower cervical segment involvement group and the non-lower cervical segment involvement group,respectively,with statistically significant differences(X2=9.400;P<0.05).10.MMR protein expression deficiency rates were 35.2% and 18.6% in the vascular infiltration group and the non-vascular infiltration group,respectively,with statistically significant differences(X2=6.440;P<0.05).11.MMR protein expression deficiency rates were 41.2% and 21.1% in the lymph node metastasis group and the non-lymph node metastasis group,respectively,with no statistically significant differences(X2=3.621;P>0.05).12.The MMR protein expression deficiency rates were 20.3%and 33.3% in FIGO I+II and III stages,respectively,with no statistically significant differences(X2=3.102;P>0.05).13.MMR protein expression deficiency rates were17.4%,17.9%,35.6%,24.0% and 33.3% in the highly differentiated group,thehighly/moderately differentiated group,the moderately differentiated group,the moderately/poorly differentiated group and the poorly differentiated group,respectively,with no statistically significant differences(X2= 0.005 P > 0.05;X2 =3.582 P>0.05;X2 = 1.082 P>0.05;X2 = 0.358 P>0.05;X2 = 1.702 P>0.05).Research conclusions:1.The endometrial cancer with MMR protein expression deficiency tends to occur in young or non-obese women.2.The pathological type of endometrial carcinoma with MMR protein expression deficiency is usually endometrioid carcinoma.3.MMR protein expression deficiency is more likely to occur in endometrial carcinoma with vascular infiltration or involvement of the lower cervical segment.4.The endometrial carcinoma with MMR protein expression deficiency had no significant correlation with the history of hypertension,diabetes,personal tumor history,family tumor history,the depth of muscle infiltration,lymph node metastasis,FIGO stage,and the degree of differentiation,but the conclusion still needs to be further studied.